|
|
|
Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy, greatly increases the lifespan of certain subsets of immune system T cells in some HIV-positive people who respond to this therapy, discovered researchers from the National Institutes of Health (NIH) Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. A report describing the study, led by the Clinical Center’s Joseph A. Kovacs, M.D., appears online in The Journal of Clinical Investigation.
A hallmark of HIV infection is the progressive loss of CD4+ T cells (a key type of white blood cell) and the subsequent decline in the infected person’s ability to fend off disease. NIH clinical investigators pioneered the experimental use of IL-2 in HIV therapy to help boost the immune systems of people with HIV infection. Produced naturally by T cells, IL-2 is a powerful immune system regulator. While its use in HIV therapy is experimental and can be associated with various side effects, IL-2 is licensed to treat certain cancers.
Message posted by: Rashmi Nemade
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|